| 4.04 0.07 (1.76%) | 05-04 12:04 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 5.09 | 1-year : | 5.51 |
| Resists | First : | 4.35 | Second : | 4.71 |
| Pivot price | 4.2  |
|||
| Supports | First : | 3.77 | Second : | 3.14 |
| MAs | MA(5) : | 3.95 |
MA(20) : | 4.21 |
| MA(100) : | 4.26 |
MA(250) : | 3.61 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 25.5 |
D(3) : | 17 |
| RSI | RSI(14): 45.8 |
|||
| 52-week | High : | 5.42 | Low : | 2.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ OBIO ] has closed above bottom band by 38.1%. Bollinger Bands are 17.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.07 - 4.09 | 4.09 - 4.11 |
| Low: | 3.87 - 3.9 | 3.9 - 3.92 |
| Close: | 3.92 - 3.97 | 3.97 - 4.01 |
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Thu, 30 Apr 2026
FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy - GlobeNewswire
Wed, 29 Apr 2026
Orchestra BioMed: RTW funds sell $132 in stock By Investing.com - Investing.com South Africa
Wed, 29 Apr 2026
Orchestra BioMed (OBIO) stake rises to 19.2% after RTW warrant exercise - Stock Titan
Wed, 29 Apr 2026
RTW funds exercise 1.25M Orchestra BioMed (NASDAQ: OBIO) pre-funded warrants - Stock Titan
Wed, 29 Apr 2026
Orchestra BioMed (NASDAQ: OBIO) seeks ESPP, director votes at 2026 meeting - Stock Titan
Sun, 26 Apr 2026
BTIG Downgrades Orchestra BioMed Holdings (OBIO) - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 59 (M) |
| Held by Insiders | 3.22e+007 (%) |
| Held by Institutions | 27.2 (%) |
| Shares Short | 795 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.148e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -157.4 % |
| Operating Margin | 21.8 % |
| Return on Assets (ttm) | -34 % |
| Return on Equity (ttm) | -109.5 % |
| Qtrly Rev. Growth | 12 % |
| Gross Profit (p.s.) | 200.33 |
| Sales Per Share | 5.58e+007 |
| EBITDA (p.s.) | 5.54833e+007 |
| Qtrly Earnings Growth | -1.2 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 2.61 |
| Dividend | 0 |
| Forward Dividend | 886630 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|